Share Price and Basic Stock Data
Last Updated: November 21, 2024, 9:37 pm
| PEG Ratio | 0.00 |
|---|
Competitors of Pharmaids Pharmaceuticals Ltd
| Stock Name | Market Cap | Current Price | High / Low | Stock P/E | Book Value | Dividend Yield | ROCE | ROE | Face Value |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Themis Biosyn Ltd | 3,465 Cr. | 318 | 390/108 | 65.7 | 20.5 | 0.21 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 59.8 Cr. | 80.6 | 94.9/25.8 | 22.9 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 28.0 Cr. | 19.1 | 19.5/8.35 | 36.3 | 6.64 | 0.00 % | 4.06 % | 3.33 % | 10.0 |
| Godavari Drugs Ltd | 85.5 Cr. | 114 | 155/87.0 | 12.8 | 55.4 | 0.00 % | 12.7 % | 15.5 % | 10.0 |
| Glenmark Life Sciences Ltd | 13,221 Cr. | 1,080 | 1,335/620 | 31.2 | 207 | 2.08 % | 28.1 % | 21.1 % | 2.00 |
| Industry Average | 15,004.70 | N/A | 43.76 | N/A | N/A | 16.25 | 16.45 | N/A |
Quarterly Result
| Month | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Expenses | 0.54 | 0.69 | 1.61 | 1.02 | 1.32 |
| Operating Profit | -0.54 | -0.69 | -1.61 | -1.02 | -1.30 |
| OPM % | -6,500.00% | ||||
| Other Income | 0.00 | 0.00 | 0.41 | -0.26 | -0.90 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | -0.55 | -0.70 | -1.21 | -1.29 | -2.21 |
| Tax % | 0.00% | 0.00% | -7.44% | 60.47% | 26.24% |
| Net Profit | -0.55 | -0.71 | -1.30 | -0.50 | -1.63 |
| EPS in Rs | -0.53 | -0.54 | -0.61 | -0.23 | -0.76 |
Last Updated: Unknown
Profit & Loss - Annual Report
Last Updated: Unknown
| Month | Mar 2022 | Mar 2023 |
|---|---|---|
| Sales | 3.94 | 0.00 |
| Expenses | 3.81 | 9.89 |
| Operating Profit | 0.13 | -9.89 |
| OPM % | 3.30% | |
| Other Income | 0.02 | 0.00 |
| Interest | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.02 |
| Profit before tax | 0.14 | -9.91 |
| Tax % | 0.00% | 23.71% |
| Net Profit | 0.15 | -7.56 |
| EPS in Rs | 0.15 | -3.52 |
| Dividend Payout % | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2022-2023 |
|---|---|
| YoY Net Profit Growth (%) | -5140.00% |
| Change in YoY Net Profit Growth (%) | 0.00% |
Pharmaids Pharmaceuticals Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 1 years from 2022-2023 to 2022-2023.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -32% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 40% |
| 5 Years: | 72% |
| 3 Years: | 68% |
| 1 Year: | 90% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -17% |
Last Updated: Unknown
Balance Sheet
Last Updated: November 14, 2024, 7:51 pm
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|
| Equity Capital | 10 | 21 | 35 | 35 |
| Reserves | -2 | 1 | 37 | 32 |
| Borrowings | 0 | 0 | 9 | 14 |
| Other Liabilities | 2 | 2 | 11 | 13 |
| Total Liabilities | 11 | 25 | 91 | 95 |
| Fixed Assets | 0 | 0 | 63 | 69 |
| CWIP | 0 | 2 | 7 | 3 |
| Investments | 0 | 3 | 0 | 0 |
| Other Assets | 11 | 19 | 21 | 22 |
| Total Assets | 11 | 25 | 91 | 95 |
Cash Flow
| Month | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
Free Cash Flow
| Month | Mar 2022 | Mar 2023 |
|---|---|---|
| Free Cash Flow | 0.13 | -9.89 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Debtor Days | 124 | 65 | |
| Inventory Days | 91 | 0 | 114 |
| Days Payable | 236 | 163 | |
| Cash Conversion Cycle | -21 | 16 | |
| Working Capital Days | -18 | -9 | |
| ROCE % | -64% | -28% |
This stock is not held by any mutual fund
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -3.56 | -5.86 | 0.14 |
| Diluted EPS (Rs.) | -3.56 | -5.86 | 0.14 |
| Cash EPS (Rs.) | -2.87 | -3.52 | 0.15 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 19.99 | 10.47 | 8.44 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 19.99 | 10.47 | 8.44 |
| Revenue From Operations / Share (Rs.) | 4.28 | 0.00 | 3.84 |
| PBDIT / Share (Rs.) | -3.50 | -4.61 | 0.14 |
| PBIT / Share (Rs.) | -3.98 | -4.62 | 0.13 |
| PBT / Share (Rs.) | -4.43 | -4.62 | 0.13 |
| Net Profit / Share (Rs.) | -3.36 | -3.52 | 0.14 |
| NP After MI And SOA / Share (Rs.) | -2.26 | -3.52 | 0.14 |
| PBDIT Margin (%) | -81.57 | 0.00 | 3.86 |
| PBIT Margin (%) | -92.99 | 0.00 | 3.63 |
| PBT Margin (%) | -103.37 | 0.00 | 3.56 |
| Net Profit Margin (%) | -78.36 | 0.00 | 3.68 |
| NP After MI And SOA Margin (%) | -52.72 | 0.00 | 3.68 |
| Return on Networth / Equity (%) | -11.05 | -33.64 | 1.67 |
| Return on Capital Employeed (%) | -17.61 | -44.09 | 1.64 |
| Return On Assets (%) | -8.72 | -30.72 | 1.30 |
| Long Term Debt / Equity (X) | 0.04 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.07 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.26 | 0.00 | 0.00 |
| Current Ratio (X) | 1.17 | 8.23 | 1.09 |
| Quick Ratio (X) | 0.85 | 8.23 | 0.72 |
| Interest Coverage Ratio (X) | -7.86 | -2135.71 | 55.63 |
| Interest Coverage Ratio (Post Tax) (X) | -6.55 | -1631.24 | 54.05 |
| Enterprise Value (Cr.) | 182.39 | 34.01 | 12.44 |
| EV / Net Operating Revenue (X) | 12.07 | 0.00 | 3.16 |
| EV / EBITDA (X) | -14.79 | -3.44 | 81.73 |
| MarketCap / Net Operating Revenue (X) | 12.14 | 0.00 | 3.26 |
| Price / BV (X) | 2.55 | 2.08 | 1.48 |
| Price / Net Operating Revenue (X) | 12.14 | 0.00 | 3.26 |
| EarningsYield | -0.04 | -0.16 | 0.01 |
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Pharmaids Pharmaceuticals Ltd:
- Net Profit Margin: -78.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -17.61% (Industry Average ROCE: 16.25%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -11.05% (Industry Average ROE: 16.45%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -6.55
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.85
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 43.76)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.07
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -78.36%
About the Company - Qualitative Analysis
Pharmaids Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 01/03/1989 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L52520TG1989PLC009679 and registration number is 009679. Currently company belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 3.94 Cr. and Equity Capital is Rs. 10.27 Cr. for the Year ended 31/03/2022.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Unit 201,, Brigade Rubix, 2nd Floor, 20/14, HMT Factory Main Road, Bengaluru Karnataka 560013 | compliance@pharmaids.com http://www.pharmaids.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Shankarappa Nagaraja Vinaya Babu | Chairman, Non Ind & Non Exe Director |
| Mr. Venu Madhava Kaparthy | Executive Director |
| Ms. Mini Manikantan | Executive Director |
| Mr. Shreedhara Shetty | Non Exe.Non Ind.Director |
| Mr. Methuku Nagesh | Independent Director |
| Mr. P N Vijay | Independent Director |
| Mr. Mopperthy Sudheer | Independent Director |
FAQ
What is the latest intrinsic value of Pharmaids Pharmaceuticals Ltd?
The latest intrinsic value of Pharmaids Pharmaceuticals Ltd as on 21 November 2024 is ₹48.84, which is 33.91% lower than the current market price of ₹73.90.
What is the Market Cap of Pharmaids Pharmaceuticals Ltd?
The Market Cap of Pharmaids Pharmaceuticals Ltd is 261 Cr..
What is the current Stock Price of Pharmaids Pharmaceuticals Ltd as on 21 November 2024?
The current stock price of Pharmaids Pharmaceuticals Ltd as on 21 November 2024 is ₹73.9.
What is the High / Low of Pharmaids Pharmaceuticals Ltd stocks in FY 2024?
In FY 2024, the High / Low of Pharmaids Pharmaceuticals Ltd stocks is 87.5/31.9.
What is the Stock P/E of Pharmaids Pharmaceuticals Ltd?
The Stock P/E of Pharmaids Pharmaceuticals Ltd is .
What is the Book Value of Pharmaids Pharmaceuticals Ltd?
The Book Value of Pharmaids Pharmaceuticals Ltd is 19.0.
What is the Dividend Yield of Pharmaids Pharmaceuticals Ltd?
The Dividend Yield of Pharmaids Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Pharmaids Pharmaceuticals Ltd?
The ROCE of Pharmaids Pharmaceuticals Ltd is 27.6 %.
What is the ROE of Pharmaids Pharmaceuticals Ltd?
The ROE of Pharmaids Pharmaceuticals Ltd is 16.8 %.
What is the Face Value of Pharmaids Pharmaceuticals Ltd?
The Face Value of Pharmaids Pharmaceuticals Ltd is 10.0.
